Literature DB >> 29605510

Immunotherapy for pancreatic cancer: A long and hopeful journey.

Jian-Wei Xu1, Lei Wang1, Yu-Gang Cheng1, Guang-Yong Zhang1, San-Yuan Hu1, Bin Zhou2, Han-Xiang Zhan3.   

Abstract

Multiple therapeutic strategies have been developed to treat pancreatic cancer. However, the outcomes of these approaches are disappointing. Due to deeper understandings of the pivotal roles of the immune system in pancreatic cancer tumorigenesis and progression, novel therapeutic strategies based on immune cells and the tumor microenvironment are being investigated. Some of these approaches, such as checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and BiTE antibodies, have achieved exciting outcomes in preclinical and clinical trials. The current review describes the roles of immune cells and the immunosuppressive microenvironment in the development of pancreatic cancer, as well as the preclinical and clinical outcomes and benefits of recent immunotherapeutic approaches, which may help us further disclose the mechanisms of pancreatic cancer progression and the dialectical views of feasibility and effectiveness of immunotherapy in treatment of pancreatic cancer.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Monoclonal antibodies; Pancreatic cancer; Tumor microenvironment; Vaccines

Mesh:

Substances:

Year:  2018        PMID: 29605510     DOI: 10.1016/j.canlet.2018.03.040

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal:  Adv Sci (Weinh)       Date:  2021-02-12       Impact factor: 16.806

2.  A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer.

Authors:  Qiangda Chen; Ning Pu; Hanlin Yin; Jicheng Zhang; Guochao Zhao; Wenhui Lou; Wenchuan Wu
Journal:  Exp Biol Med (Maywood)       Date:  2021-10-09

3.  Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model.

Authors:  Said Ahmed Bahwal; Jane J Chen; Lilin E; Taofang Hao; Jiancong Chen; Vern B Carruthers; Jiaming Lai; Xingwang Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-12       Impact factor: 4.322

Review 4.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

5.  Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12D p53LSL-R172H Pdx1-Cre mouse model.

Authors:  Su Hu; Jia Yang; Junjie Shangguan; Aydin Eresen; Yu Li; Quanhong Ma; Vahid Yaghmai; Yuri Velichko; Chunhong Hu; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

Review 6.  Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.

Authors:  Jia Wu; Jianting Cai
Journal:  Dig Dis Sci       Date:  2020-03-05       Impact factor: 3.199

7.  Bibliometric Analysis of Tumor Immunotherapy Studies.

Authors:  Kaining Lu; Shan Yu; Meng Yu; Dan Sun; Zhihong Huang; Haotian Xing; Jianbin Bi; Zeliang Li; Zhenhua Li; Xiankui Liu; Chuize Kong; Yuyan Zhu
Journal:  Med Sci Monit       Date:  2018-05-23

8.  CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.

Authors:  Qiangda Chen; Ning Pu; Hanlin Yin; Jicheng Zhang; Guochao Zhao; Wenhui Lou; Wenchuan Wu
Journal:  J Cell Mol Med       Date:  2020-07-09       Impact factor: 5.310

Review 9.  Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.

Authors:  Samia S Messeha; Najla O Zarmouh; Karam F A Soliman
Journal:  Nutrients       Date:  2021-05-19       Impact factor: 5.717

Review 10.  Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.

Authors:  Jun Gong; Andrew Hendifar; Richard Tuli; Jeremy Chuang; May Cho; Vincent Chung; Daneng Li; Ravi Salgia
Journal:  Clin Transl Med       Date:  2018-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.